Effect of Drug, Drug, Toxicity
Conditions
Keywords
Osteosarcoma, Apatinib, Ifosfamide, Etoposide
Brief summary
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse than that of pulmonary lesions. This treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE). We have ever retrospectively compared the activity of apatinib + IE in relapsed or refractory osteosarcoma in two sarcoma centers in China and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + IE demonstrated clinically meaningful antitumor activity and delayed disease progression in patients with recurrent or refractory osteosarcoma after failure of chemotherapy. However to overcome the influence of other interventions on the outcome, we are currently performing a prospective trial to investigate this combination, from which more accurate data on this treatment strategy are expected.
Interventions
DRUGApatinib+IE
apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
DRUGIE
ifosfamide ivgtt ; etoposide ivgtt .
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Peking University People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. advanced recurrent and refractory osteosarcoma confirmed by histopathology; 2. initial treatment in the Orthopedic/Oncology Departments of Peking University People's Hospital or Peking University Shougang Hospital; 3. progression less than 6 months after first-line chemotherapy with a combination of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide (first-line chemotherapy); 4. measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1) ; 5. Eastern Cooperative Oncology Group performance status ≤ 1 ; 6. acceptable haematologic, hepatic, and renal function.
Exclusion criteria
1. those who had been previously treated with antiangiogenic TKIs and single IE chemotherapy; 2. those who had severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. These confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction\<50%, and hypertension that could not be well controlled with antihypertensive drugs.; 3. all patients were assessed by the sarcoma board including a thoracic surgeon with at least 10 years surgical experience. Patients with lung metastases only were carefully assessed for eligibility for metastasectomy, of whom those who were suitable for surgery were excluded from this study; 4. weight loss of 20% or more before illness; 5. brain or leptomeningeal metastasis; 6. surgical procedure or radiotherapy within 4 weeks of enrollment; 7. activegastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation; 8. proteinuria or hematuria, denutrition with albuminemia \<25 g/L; 9. women who were pregnant or breast feeding, other malignancy; 10. positive HBV/HCV/HIV serology, and known allergy to the experimental agents.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 2 years | from the start of target treatment until disease progression or death, whichever came first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 3 years | from the date of treatment initiation to death from any cause. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate | 2 years | defined as the proportion of subjects whose best overall response (BOR) is complete response (CR), partial response (PR) and stable disease (SD), evaluated by investigator based on RECIST v1.1. |
| Duration of response | 2 years | defined as the time from first unconfirmed complete response (CR)/ unconfirmed partial response (PR), evaluated by investigator based on RECIST v1.1, to progressive disease (PD) or any cause of death, whichever occurs first. |
| Time to response | 2 years | defined as the time from randomization to first CR/PR, evaluated by investigator based on RECIST v1.1. |
| Time to progress | 2 years | defined as the time from randomization to progress disease, evaluated by nvestigator based on RECIST v1.1 |
| Progression-free survival at 4 months | 2 years | defined as the percentage of patients who were alive and free of disease progression at 4 months evaluated by investigator based on RECIST v1.1 |
| Progression-free survival at 6 months | 2 years | defined as the percentage of patients who were alive and free of disease progression at 6 months evaluated by investigator based on RECIST v1.1 |
| Objective response rate | 2 years | defined as the proportion of subjects whose best overall response (BOR) is CR or PR, evaluated by investigator based on RECIST v1.1 |
Countries
China
Outcome results
None listed